ProfileGDS5678 / 1422873_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 24% 25% 25% 26% 24% 29% 24% 25% 24% 25% 24% 24% 24% 24% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.5942724
GSM967853U87-EV human glioblastoma xenograft - Control 22.5716425
GSM967854U87-EV human glioblastoma xenograft - Control 32.5762225
GSM967855U87-EV human glioblastoma xenograft - Control 42.5441526
GSM967856U87-EV human glioblastoma xenograft - Control 52.522224
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.7320929
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.591224
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.556425
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.5313524
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.570925
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.5559424
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.5342624
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.5625724
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.562524